首页> European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)> A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Amadori D

作者： Amadori D ^[1] ; Milandri C ; Comella G ; Saracchini S ; Salvagni S ; Barone C ; Bordonaro R ; Gebbia V ; Barbato A ; Serra P ; Gattuso D ; Nanni O ; Baconnet B ; Gasparini G

作者单位： Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

European journal of cancer

2011年47卷14期

2091-2098页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

European journal of cancer

2011年47卷14期

2091-2098页

检索历史清除

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

European journal of cancer

相似文献

同项目论文

European journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

European journal of cancer

相似文献

同项目论文

European journal of cancer

相关期刊

检索历史清除